Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101.
暂无分享,去创建一个
Sonke Svenson | Marc Wolfgang | S. Eliasof | J. Ryan | S. Svenson | Jungyeon Hwang | Scott Eliasof | John Ryan | Jungyeon Hwang | Marc Wolfgang | Sőnke Svenson
[1] S. Arbuck,et al. Camptothecin and Its Analogs , 1996 .
[2] Jianjun Cheng,et al. Pharmacokinetics and biodistribution of the camptothecin–polymer conjugate IT-101 in rats and tumor-bearing mice , 2006, Cancer Chemotherapy and Pharmacology.
[3] A. Gabizon,et al. The role of surface charge and hydrophilic groups on liposome clearance in vivo. , 1992, Biochimica et biophysica acta.
[4] S. Arbuck,et al. Camptothecin and its analogs. An overview of their potential in cancer therapeutics. , 1996, Annals of the New York Academy of Sciences.
[5] Jianjun Cheng,et al. Antitumor Activity of β-Cyclodextrin Polymer−Camptothecin Conjugates , 2004 .
[6] Jianjun Cheng,et al. Synthesis of linear, beta-cyclodextrin-based polymers and their camptothecin conjugates. , 2003, Bioconjugate chemistry.
[7] R. Hertzberg,et al. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. , 1989, Biochemistry.
[8] Mark E. Davis,et al. Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements , 2009, Proceedings of the National Academy of Sciences.
[9] Jianjun Cheng,et al. Preclinical Efficacy of the Camptothecin-Polymer Conjugate IT-101 in Multiple Cancer Models , 2006, Clinical Cancer Research.
[10] F. Martin,et al. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. , 1992, Cancer research.
[11] C. Lee,et al. Camptothecin-20-PEG ester transport forms: the effect of spacer groups on antitumor activity. , 1998, Bioorganic & medicinal chemistry.
[12] F. Bertucci,et al. Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis. , 2008, Cancer research.
[13] H. Maeda,et al. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.
[14] T. Burke,et al. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. , 1994, Journal of medicinal chemistry.
[15] A. McPhail,et al. Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2 , 1966 .
[16] Jianjun Cheng,et al. Anticancer Polymeric Nanomedicines , 2007 .
[17] Mark E. Davis,et al. Preclinical Results of Camptothecin-Polymer Conjugate (IT-101) in Multiple Human Lymphoma Xenograft Models , 2009, Clinical Cancer Research.
[18] M. Woodle,et al. Sterically stabilized liposomes. , 1992, Biochimica et biophysica acta.
[19] Mark E. Davis,et al. Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.
[20] J. Verweij,et al. Modulation of camptothecin analogs in the treatment of cancer: a review , 2001, Anti-cancer drugs.
[21] T. Burke,et al. Differential interactions of camptothecin lactone and carboxylate forms with human blood components. , 1994, Biochemistry.